NGFR and osteosarcoma: Moreover, CD271 monoclonal antibody was also used as a bone-targeting agent to localize PTAs in osteosarcomas, as CD271 was demonstrated to be overexpressed on the surface of osteosarcoma cancer stem cells [226].